CR9647A - Moduladores de cinasa de aminoquinolina y amoniquinazolina - Google Patents

Moduladores de cinasa de aminoquinolina y amoniquinazolina

Info

Publication number
CR9647A
CR9647A CR9647A CR9647A CR9647A CR 9647 A CR9647 A CR 9647A CR 9647 A CR9647 A CR 9647A CR 9647 A CR9647 A CR 9647A CR 9647 A CR9647 A CR 9647A
Authority
CR
Costa Rica
Prior art keywords
compounds
aminoquinoline
trkb
flt3
amoniquinazoline
Prior art date
Application number
CR9647A
Other languages
English (en)
Inventor
Baindur Nand
David Gaul Michael
Douglas Kreutter Kevin
Andrew Baumann Chiristian
Xu Guozhang
J Kim Alexander
Zhao Bao-Ping
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9647A publication Critical patent/CR9647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion esta dirigida a compuestos de aminoquinolina y aminoquinazolina de la formula I, en donde R1, R2, R3, B, Z, Q, p, q y X son como se define aqui, el uso de dichos compuestos como moduladores de proteina tirosina cinasa, particularmente inhibidores de FLT3 y/o TrkB, el uso de dichos compuestos para reducir o inhibir la actividad de cinasa de FLT3 y/o TrkB en una celula o un sujeto, y el uso de dichos compuestos para prevenir o tratar en un sujeto un trastorno proliferativo de celulas y/o trastornos relacionados con FLT3 y/o TrkB; la presente invencion ademas esta dirigida a composiciones farmaceuticas que comprenden los compuestos de la presente invencion y a metodos para tratar condiciones tales como canceres y otros trastornos proliferativos de celulas.
CR9647A 2005-06-10 2008-01-09 Moduladores de cinasa de aminoquinolina y amoniquinazolina CR9647A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938205P 2005-06-10 2005-06-10
US74732106P 2006-05-16 2006-05-16

Publications (1)

Publication Number Publication Date
CR9647A true CR9647A (es) 2008-09-09

Family

ID=37101582

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9647A CR9647A (es) 2005-06-10 2008-01-09 Moduladores de cinasa de aminoquinolina y amoniquinazolina

Country Status (17)

Country Link
US (1) US20070004763A1 (es)
EP (1) EP1899319A2 (es)
JP (1) JP2008543762A (es)
KR (1) KR20080028913A (es)
AR (1) AR057062A1 (es)
AU (1) AU2006258059A1 (es)
BR (1) BRPI0611621A2 (es)
CA (1) CA2611378A1 (es)
CR (1) CR9647A (es)
EA (1) EA200800014A1 (es)
EC (1) ECSP077998A (es)
GT (1) GT200600254A (es)
IL (1) IL187685A0 (es)
NO (1) NO20080168L (es)
PE (1) PE20070113A1 (es)
TW (1) TW200716598A (es)
WO (1) WO2006135649A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JP6903585B2 (ja) * 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
KR20190004742A (ko) * 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2018034917A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
MX2020002646A (es) 2017-09-08 2020-09-25 Univ Leland Stanford Junior Inhibidores de enpp1 y su uso para el tratamiento del cancer.
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
EP3813819A4 (en) 2018-06-29 2022-08-17 Kinnate Biopharma Inc. CYCLIN-DEPENDENT KINASE INHIBITORS
EP3825303A4 (en) 2018-07-17 2022-07-06 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
CA3135344A1 (en) * 2019-03-29 2020-10-08 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
CN114401955A (zh) * 2019-07-17 2022-04-26 金耐特生物制药公司 细胞周期蛋白依赖性激酶的抑制剂
JP7584623B2 (ja) * 2020-07-23 2024-11-15 シトシンラボ セラピューティクス カンパニー， リミテッド キナーゼ阻害活性を有する化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT344178B (de) * 1974-07-25 1978-07-10 Pfizer Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
DE60227794D1 (de) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
IL165871A0 (en) * 2002-06-27 2006-01-15 Schering Ag Substituted quinoline CCR5 receptor antagonists
ES2344007T3 (es) * 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.

Also Published As

Publication number Publication date
PE20070113A1 (es) 2007-02-09
WO2006135649A2 (en) 2006-12-21
KR20080028913A (ko) 2008-04-02
AU2006258059A1 (en) 2006-12-21
NO20080168L (no) 2008-03-07
CA2611378A1 (en) 2006-12-21
EA200800014A1 (ru) 2008-06-30
AR057062A1 (es) 2007-11-14
WO2006135649A3 (en) 2007-02-15
IL187685A0 (en) 2008-08-07
GT200600254A (es) 2007-01-12
US20070004763A1 (en) 2007-01-04
BRPI0611621A2 (pt) 2010-09-21
EP1899319A2 (en) 2008-03-19
JP2008543762A (ja) 2008-12-04
ECSP077998A (es) 2008-01-23
TW200716598A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
CR9647A (es) Moduladores de cinasa de aminoquinolina y amoniquinazolina
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
NI200800179A (es) Triazolopiridazinas como moduladores de la tirosina cinasa
CR9652A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
CO6270257A2 (es) Derivados de piridazinona
CL2011002946A1 (es) Compuestos derivados de tiazoltiadiazol aminopirazol, inhibidores de proteina quinasa c-met; composicion farmaceutica que los comprende y su uso en el tratamiento de diferentes tipos de cancer.
EA200702136A1 (ru) Композиции станнсопорфина и их применение
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
GT200600250A (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)